CEACAM5 and neoplasm: A circulating marker which can better reflect the process of bone metabolism is needed in the management of women with bony metastases from breast cancer, in addition to currently available markers of tumour load (eg MUC1 mucin measured as cancer antigen 15.3 (CA15.3), carcinoembryonic antigen (CEA)).